Shenyang Pharma Univ. ROCK2 compound A25

Shenyang Pharma Univ. ROCK2 compound A25: sourced facts only. name: "Through comprehensive investigation of SARs, compounds A25 and A26 exhibited superior ROCK2 inhibitory potency (IC50 = 7.0 and 8.7 nM, respectively) and excellent isoform selectivity (SI = 200/138)." [PMID:41042904]; target: "Through comprehensive investigation of SARs, compounds A25 and A26 exhibited superior ROCK2 inhibitory potency (IC50 = 7.0 and 8.7 nM, respectively) and excellent isoform selectivity (SI = 200/138)." [PMID:41042904]; developer: "Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China." [PMID:41042904]; stage: "In bleomycin-induced PF mice models, administration of A25 and A26 resulted in a pronounced reduction of collagen deposition and a significant reversal of fibrotic progression." [PMID:41042904]